Learn More
Hepatitis B virus (HBV) infection is a common infectious disease. Here we perform a genome-wide association study (GWAS) among Chinese populations to identify novel genetic loci involved in persistent HBV infection. GWAS scan is performed in 1,251 persistently HBV infected subjects (PIs, cases) and 1,057 spontaneously recovered subjects (SRs, controls),(More)
EpCAM: A Potential Antimetastatic Target for Gastric Cancer by Wenqi Du, Hongzan Ji, Shanshan Cao, Li Wang, Feihu Bai, Jie Liu, Daiming Fan published online in Digestive Diseases and Sciences on November 26, 2009, DOI 10.1007/s10620-009-1033-8 is retracted as the article plagiarized the content from the following article: EpCAM is overexpressed in gastric(More)
The coinhibitory receptor Programmed Death-1 (PD-1) inhibits effector functions of activated T cells and prevents autoimmunity, however, cancer hijack this pathway to escape from immune attack. The costimulatory receptor glucocorticoid-induced TNFR related protein (GITR) is up-regulated on activated T cells and increases their proliferation, activation and(More)
Hypoxia inducible factor-1α (HIF-1α) was well correlated with carcinogenesis and tumor progression in many kinds of cancer. In this study, high expression of HIF-1α was found in 37 of the 72 (51.39%) tumor specimens, and significantly correlated with venous invasion and lymphonode invasion. Patients with high expression of HIF-1α had a significantly shorter(More)
OBJECTIVE HJURP (Holliday Junction-Recognizing Protein) plays dual roles in DNA repair and in accurate chromosome segregation during mitosis. We examined whether the single nucleotide polymorphisms (SNPs) of HJURP were associated with the risk of occurrence of hepatocellular carcinoma (HCC) among chronic hepatitis B virus (HBV) carriers from well-known(More)
Epithelial cellular adhesion molecule (EpCAM) is an attractive immunotherapeutic target to overcome metastasis of a variety of epithelium-oriented cancers. Edrecolomab, one kind of EpCAM monoclonal antibody (Panorex®), has been approved for clinical application as postoperative adjuvant therapy in breast and colorectal cancer. However, the role of EpCAM in(More)
  • 1